GlaxoSmithKline PLC ADR (GSK)vsTeck Resources Ltd Class B (TECK)
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
TECK
Teck Resources Ltd Class B
$50.36
+3.71%
BASIC MATERIALS · Cap: $23.82B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 204% more annual revenue ($32.67B vs $10.76B). GSK leads profitability with a 17.5% profit margin vs 13.0%. GSK appears more attractively valued with a PEG of 0.50. TECK earns a higher WallStSmart Score of 73/100 (B).
GSK
Strong Buy70
out of 100
Grade: B
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Margin of Safety
+37.4%
Fair Value
$96.41
Current Price
$50.36
$46.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 32.6%
Growing faster than its price suggests
Earnings expanding 42.5% YoY
Areas to Watch
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Grey zone — moderate risk
ROE of 4.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : TECK
The strongest argument for TECK centers on Price/Book, Operating Margin, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
GSK profiles as a mature stock while TECK is a value play — different risk/reward profiles.
TECK carries more volatility with a beta of 1.53 — expect wider price swings.
TECK is growing revenue faster at 9.8% — sustainability is the question.
GSK generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
TECK scores higher overall (73/100 vs 70/100). GSK offers better value entry with a 66.0% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?